Drugs / Cellavita HD
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02728115 | Oct 2017 → Dec 2022 | Huntington disease | Azidus Brasil | Unknown | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03252535 | Jan 2018 → Mar 2021 | Huntington disease | Azidus Brasil | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04219241 | Feb 2020 → Dec 2022 | Huntington disease | Azidus Brasil | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cellavita HD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02728115 ↗ |
| Known as | NestaCell | “Clarification: The investigational product evaluated in this study was originally developed under the name Cellavita HD. In March 2020, it was registered under the trademark...” PMID 41188963 ↗ Nov 20251“In March 2020, it was registered under the trademark NestaCell®. Both names refer to the same cell-based product.” PMID 40770775 ↗ Aug 2025 |
| Modality | Cell therapy | “Cellavita HD is a stem-cell therapy for Huntington's Disease.” NCT03252535 ↗ |
| Route | Intravenous | “Six male patients with HD received intravenous infusions of hDPSCs in two dosage cohorts” PMID 41188963 ↗ Nov 2025 |